Turmeric Safety and Drug Interactions
Turmeric has one of the best safety records of any plant humans eat. It has been a daily seasoning across South Asia for well over a thousand years, eaten by hundreds of millions of people in quantities that would take a very long clinical trial to replicate. Nothing on this page changes that. For people who cook with turmeric, nothing in the safety literature on this page is an argument against it.
What changed is the supplement. A modern curcumin capsule is not the spice in a smaller package. It is a concentrated extract — often standardised to 95% curcuminoids, frequently paired with black-pepper extract or a lipid carrier engineered specifically to defeat the body's habit of throwing curcumin away — and it can deliver, in one swallow, more curcumin than a heavy curry-eater gets in weeks. The dose changed, the chemistry changed, and a small number of real risks appeared that track that change rather than tracking the spice.
This leg of the site covers those risks honestly, in four articles. The largest is liver injury: a genuine, prospectively documented signal in people taking concentrated supplements, set against a genuine argument that these events are rare relative to an enormous number of users. Both of those things are true at once, and the page that explains why is the most useful thing here. The others are drug interactions, lead adulteration in the global turmeric supply, and a group-by-group guide to the people the research raises concerns for.
Deep-Dive Articles
Turmeric and Liver Injury: What the Cases Show
The ten prospectively collected US cases from the Drug-Induced Liver Injury Network, the Italian and Australian reports, the genetic association observed in a subset of patients, and the pharmacopeial review arguing these events are rare. What to watch for, and why almost every case involves a concentrated supplement.
Read the deep dive →Turmeric Drug Interactions
Sorted by how good the evidence actually is: a human study showing curcumin raised sulfasalazine exposure through a gut transporter, three transplant case reports, the blood-thinner question answered honestly, iron, and why black pepper in the capsule is itself part of the interaction profile.
Read the deep dive →Lead in Turmeric: Adulteration and Product Quality
Why lead chromate ended up in turmeric, how much of South Asia's supply carried it, what it did to children's blood-lead levels — and the measurement showing that enforcement worked and adulteration fell. Plus how tested turmeric can be identified.
Read the deep dive →Who the Research Raises Concerns For
Group by group: gallstones, calcium-oxalate kidney stones, iron deficiency, upcoming surgery, transplant recipients, narrow-therapeutic-index drugs, existing liver disease and pregnancy. What the dose was in the trials, and why parts of the curcumin literature need reading with care.
Read the deep dive →Table of Contents
The Short Version
These seven lines are the short version of this leg.
- Turmeric as a cooking spice is not the problem. No part of the safety literature on this page is an argument against turmeric in food. The documented harms cluster almost entirely around concentrated extracts taken as supplements, usually at doses many times the culinary range, and very often in formulations designed to push far more curcumin into the blood than the spice ever could.
- The liver signal is real and it is small. The Drug-Induced Liver Injury Network in the United States collected ten turmeric-associated cases prospectively and published them in 2023; Italian, Australian and other reports describe the same picture. Some cases were severe. At the same time, a 2026 US Pharmacopeia review argues these events are rare set against the sheer number of people taking these products. Both statements survive scrutiny, and the liver article explains how.
- The DILIN cases in numbers: the ten cases were enrolled between 2004 and 2022, all of them since 2011 and 6 since 2017. Five patients were hospitalized, and 1 died of acute liver failure. Seven of the 10 carried the immune-system gene type HLA-B*35:01, an allele frequency of 0.450 against 0.056-0.069 in population controls. Chemical analysis confirmed turmeric in all 7 products tested, and 3 also contained piperine (black pepper). The injury typically appeared after 1 to 4 months.
- The 2026 USP review: the US Pharmacopeia's expert committee recommends adding a cautionary statement to its turmeric and curcuminoid monographs: "Liver problems have been reported very rarely in people taking supplements containing turmeric and/or curcuminoids." It found that numerous clinical trials of these supplements have not reported organ toxicity or serious adverse events, that published case reports "often involve concomitant medications or supplements", that reported liver injury "typically occurs after 1 to 4 months of use and generally resolves upon discontinuation", and that cases of acute liver failure have been reported, "albeit rarely".
- Absorption-enhanced products are a different dose. A phytosome, micelle or lipid-particle curcumin at "500 mg" is not chemically equivalent to 500 mg of plain powder. The whole point of those formulations is to deliver several times more curcumin into circulation. That difference applies to the safety literature and to the label alike.
- The best-documented drug interaction is not the one people expect. It is not warfarin. It is sulfasalazine, where curcumin raised drug exposure in healthy volunteers by inhibiting a gut transporter called BCRP. In eight healthy Japanese volunteers, taking 2 g of curcumin tablets before sulfasalazine raised the amount of the drug in the blood (the area under the curve, AUC) 2.0-fold at microdoses and 3.2-fold at therapeutic doses. That is a human study, and it is the strongest interaction finding in this pack.
- Transplant recipients are the group the case reports single out. Case reports describe tacrolimus and calcineurin-inhibitor problems after turmeric intake. When a medicine's therapeutic window is narrow, a modest shift in blood level is not a footnote.
- Product quality is a separate risk from the plant. Lead chromate adulteration of turmeric was a real public-health problem across parts of South Asia, measured in children's blood. It is also a rare case of a contamination story with a good ending: enforcement measurably reduced it. In Bangladesh, after a 2017–2021 campaign of news coverage, education and enforcement with a rapid lead test, the share of market turmeric samples with detectable lead fell "from 47% pre-intervention in 2019 to 0% in 2021 (n = 631)"; mills with lead chromate pigment on site fell from 30% to 0%, and the blood lead of mill workers dropped a median of 30%.
- New jaundice, dark urine, pale stools, itching, right-upper-abdomen pain or unexplained exhaustion while taking a turmeric supplement are signs of liver injury that hospitals treat as urgent. The caution the 2026 USP review recommends for turmeric supplements reads: "Stop using this product if you develop symptoms such as abdominal pain, dark urine, or jaundice (yellowing of the skin or eyes), and seek medical advice." Liver injury of this kind usually reverses when the supplement stops, and stopping early is most of what makes the outcome good.
Spice vs Supplement — The Distinction That Explains Most of This Page
Almost every apparent contradiction in turmeric's safety literature dissolves once you separate two things that share a name.
Turmeric the spice is the dried, ground rhizome of Curcuma longa. By weight it is mostly starch and fibre. Curcuminoids — the yellow pigments, of which curcumin is the best known — make up somewhere in the low single-digit percentages of the powder, and they vary a great deal between harvests and suppliers. On top of that, curcumin in this form is famously badly absorbed: it dissolves poorly in water, degrades at intestinal pH, and whatever survives is conjugated and shipped out by the liver and gut wall within minutes. A generous culinary intake — a heavily spiced diet, day after day — produces blood curcumin concentrations that are low by any pharmacological standard. That is the exposure under which turmeric compiled its long, quiet safety record.
Turmeric the supplement is a different object. A standardised extract concentrates curcuminoids to around 95% of the capsule's active content, which is roughly a twenty- to thirtyfold concentration step before you have swallowed anything. Then the formulation step does the rest of the work. Black-pepper extract blocks the enzymes that would otherwise dispose of absorbed curcumin. Phospholipid complexes, submicron colloids, solid lipid particles and micelles each attack a different part of the absorption problem. The combined result is intentional and well documented: these products are engineered to put many times more curcumin into the blood than the same nominal milligrams of plain powder. Our page on bioavailability and forms covers the engineering in detail, because it is also what makes the benefits literature work.
So when a case series reports liver injury in people taking turmeric, the sentence that matters is which turmeric. In the published cases it is essentially always the capsule, frequently an enhanced-absorption capsule, often at multi-gram daily doses, and sometimes taken for months. Reading those cases as a warning about curry is a category error — and it is a costly one, because it frightens people away from a food that is doing them no harm while telling them nothing useful about the product that might.
The reverse error is just as bad. "It's only a spice, it's natural, it's been used for centuries" is the argument that talks somebody with a transplant, or a bile-duct problem, or a two-gram-a-day habit and yellowing eyes, out of taking a real signal seriously. Centuries of culinary use are evidence about culinary doses. They are not evidence about a formulation invented in the last twenty years.
Who the Research Raises Concerns For — Quick Reference
This list is about supplements. With the exception of the gallbladder and oxalate entries, where large culinary doses can matter at the margins, none of it is a reason to stop cooking with turmeric. The group-by-group article takes each group in turn.
- Anyone with active gallstones or a blocked bile duct. Curcumin makes the gallbladder contract — that is measurable on ultrasound in healthy volunteers (in a crossover study of 12 of them, 20 mg of curcumin reduced gallbladder volume by 29.3% at 2 hours), and it is exactly the wrong thing to ask of a gallbladder with a stone in the neck.
- People who form calcium-oxalate kidney stones. In a human crossover study, turmeric raised urinary oxalate excretion while cinnamon did not. For oxalate stone-formers on a low-oxalate diet, that puts high-dose turmeric into the oxalate count.
- People with iron deficiency or borderline iron stores. Curcumin binds iron, and there is a published case of iron-deficiency anaemia attributed to high-dose turmeric that corrected when it stopped.
- Anyone with surgery, a dental extraction or a procedure coming up. The bleeding concern is theoretical rather than proven: in a 2018 study, 10 days of a curcumin formulation did not change bleeding time in people taking aspirin, ticlopidine or clopidogrel, or the INR in people taking warfarin or dabigatran. No study listed here tested stopping turmeric before surgery.
- Transplant recipients, and anyone on a narrow-therapeutic-index medicine. Tacrolimus and cyclosporine are the documented examples. Where small changes in blood level have large consequences, an added unmeasured variable is a real risk.
- People taking sulfasalazine, or other drugs handled by the BCRP transporter. This is the single best human interaction evidence in the whole file.
- People who already have liver disease, or who drink heavily. Not because turmeric is proven to worsen it, but because a liver with less reserve has less room to absorb an idiosyncratic injury, and because the early signs are harder to read against a background of abnormal tests.
- People taking several supplements at once, especially "stacks" that share absorption enhancers. Piperine does not only enhance curcumin. It raises exposure to plenty of other things, including prescription drugs.
- Pregnancy and breastfeeding. Culinary amounts are regarded as fine and always have been. Supplement-level doses are simply not well studied, which is a different statement from "known to be harmful".
What to Watch For
Drug-induced liver injury is uncommon, but it announces itself in a fairly consistent way, and the announcement is easy to mistake for a virus or a bad week. In someone taking a turmeric supplement, the signs below are signs of liver injury that hospitals treat as urgent. The caution the 2026 USP review recommends says to stop the product if symptoms such as abdominal pain, dark urine or jaundice develop, and to seek medical advice. Liver injury is checked with ordinary liver blood tests, and the exact product — the formulation name and the dose on the label — matters more than the word "turmeric".
- Yellowing of the whites of the eyes or the skin (jaundice). Often noticed by somebody else first, and often noticed in daylight rather than indoors.
- Dark urine — tea- or cola-coloured — especially if it persists when you are drinking normally.
- Pale, clay-coloured or unusually light stools.
- Pain, fullness or tenderness under the right ribs.
- Itching without a rash, sometimes worse at night.
- Unusual fatigue, loss of appetite or nausea that has no other explanation, particularly if it has crept up over days to weeks.
Two things make this less frightening than it reads. The first is that in the published series, stopping the supplement was usually followed by recovery. The second is that the tests are ordinary, cheap and fast: a standard liver panel answers the question the same day in most places. The bad outcomes in the literature are concentrated among people who kept taking the product after symptoms started, sometimes for weeks, occasionally because they believed a liver-supporting supplement could not be the thing hurting the liver.
How Much Counts as a Lot
It helps to have real numbers for scale, and the cleanest ones come from the phase I trials that gave curcumin to patients deliberately, under supervision, to find out what the body would tolerate.
Those trials went high. The Taiwanese phase I study escalated oral curcumin in patients with high-risk or pre-malignant lesions; the Leicester group gave oral Curcuma extract to patients with colorectal cancer and tracked what reached the blood and the tissue; a later Japanese phase I study did the same work with a highly bioavailable colloidal formulation. Read together, they show two things that are useful to a general reader. Gram-level daily doses were tolerated by most participants in short, monitored courses. And the reason the doses had to be so large in the unenhanced studies is precisely the absorption problem — the body was discarding most of it.
Set that against the spice. Even a diet rich in turmeric delivers curcuminoids in the hundreds of milligrams per day at the outside, most of which never reaches the bloodstream intact. Set it also against the modern enhanced supplement, where a few hundred milligrams on the label can produce blood levels that plain powder could not reach at ten times the dose. "How many milligrams" is not the whole question. "How many milligrams, in what formulation, for how long" is.
Two facts bear on how long and how much: the DILIN liver-injury cases appeared after 1 to 4 months of use, and the trials that found gram doses tolerated used short, monitored courses.
How to Read a Turmeric Safety Headline
Turmeric generates a steady stream of alarming and reassuring coverage, often in the same week, and the two are usually describing different things. Four questions separate signal from noise.
- Spice or extract? If the article does not say, it is not reporting carefully. Nearly every serious safety finding in this leg concerns an extract.
- Humans, animals, or cells in a dish? This matters enormously and is the most common place popular coverage goes wrong. A finding in cultured liver cells is a hypothesis about people, not a fact about them. We tag the evidence tier on every claim in these articles for exactly this reason — the drug-interactions page, for example, is careful to say that a study of warfarin and curcumin in pig liver cells is a study of pig liver cells.
- How many people, and found how? A prospectively collected series — where a network of hospitals enrols suspected cases, adjudicates them and publishes what it finds — carries more weight than a single retrospective report, which in turn carries more than a database count of unverified reports. The DILIN series is the first kind.
- Rare compared to what? A count of adverse events means little without the size of the exposed population. That is the core of the pharmacopeial argument on the other side of the liver question, and it is a legitimate argument, not a defensive one.
Applied consistently, those four questions leave you with a modest, stable picture: a spice that is safe, a supplement class that is usually well tolerated and occasionally causes real harm, a short list of drugs worth checking, and a supply-chain issue that got better because somebody measured it.
Key Research Papers
- Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. — PubMed PMID: 36252717
- Akhtar N, Barnes J, Gardiner P, et al. (2026). Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. Pharm Biol. — PubMed PMID: 42364655
- Lombardi N, Crescioli G, Maggini V, et al. (2021). Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. Br J Clin Pharmacol. — PubMed PMID: 32656820
- Halegoua-DeMarzio D, Navarro V. (2025). Challenges in herbal-induced liver injury identification and prevention. Liver Int. — PubMed PMID: 39136211
- Kusuhara H, Furuie H, Inano A, et al. (2012). Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol. — PubMed PMID: 22300367
- Hu S, Belcaro G, Dugall M, et al. (2018). Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva). Eur Rev Med Pharmacol Sci. — PubMed PMID: 30070343
- Nayeri A, Wu S, Adams E, et al. (2017). Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant Proc. — PubMed PMID: 28104136
- Forsyth JE, Mistree D, Nash E, et al. (2024). Evidence of turmeric adulteration with lead chromate across South Asia. Sci Total Environ. — PubMed PMID: 39053552
- Forsyth JE, Baker M, Nurunnahar S, et al. (2023). Food safety policy enforcement and associated actions reduce lead chromate adulteration in turmeric across Bangladesh. Environ Res. — PubMed PMID: 37286126
- Tang M, Larson-Meyer DE, Liebman M. (2008). Effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids, and plasma glucose in healthy subjects. Am J Clin Nutr. — PubMed PMID: 18469248
- Rasyid A, Lelo A. (1999). The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther. — PubMed PMID: 10102956
- Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. J Med Chem. — PubMed PMID: 28074653
PubMed Topic Searches
Connections
- Turmeric
- Turmeric Benefits
- Bioavailability and Forms
- Liver Health and Detox
- Anti-Inflammatory and Joint Health
- Brain Health and Cognition
- Turmeric and Digestive Health
- Heart and Metabolic Health
- History of Turmeric
- Javanese Turmeric
- Black Turmeric
- Fingerroot
- Culinary and Spice Herbs
- Gut Health
- Herbs